Information related the press release issued on May 24, 2023 by Alvotech and Advanz Pharma with the heading "Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe".

Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and...

  Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022Confirmatory patient study for AVT05, a proposed biosimilar for Simponi®...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan...

Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020Alvotech’s Equality Policy, which is...

Polifarma will commercialize AVT06, a proposed biosimilar to Eylea® (aflibercept), in Turkey  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of...

The Annual General Meeting of Alvotech S.A. will be held on Tuesday 6 June 2023, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg,...

The clinical study will compare AVT05 and Simponi® in patients with moderate to severe rheumatoid arthritis Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...